Ian A. MacNeil

2.7k total citations · 2 hit papers
25 papers, 2.0k citations indexed

About

Ian A. MacNeil is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ian A. MacNeil has authored 25 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ian A. MacNeil's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Protein Kinase Regulation and GTPase Signaling (6 papers) and HER2/EGFR in Cancer Research (5 papers). Ian A. MacNeil is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Protein Kinase Regulation and GTPase Signaling (6 papers) and HER2/EGFR in Cancer Research (5 papers). Ian A. MacNeil collaborates with scholars based in United States and Japan. Ian A. MacNeil's co-authors include Tatsuo Kina, Nobuko Uchida, Yueh‐hsiu Chien, Bruno Péault, Irving L. Weissman, Koichi Ikuta, Berkley A. Lynch, Marcia S. Osburne, Kara A. Loiacono and Trudy H. Grossman and has published in prestigious journals such as Cell, Journal of Clinical Oncology and Journal of Molecular Biology.

In The Last Decade

Ian A. MacNeil

24 papers receiving 1.8k citations

Hit Papers

Cloning the Soil Metagenome: a Strategy for Accessing the... 1990 2026 2002 2014 2000 1990 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cloning the Soil Metagenome: a Strategy for Accessing the Genetic and Functional Diversity of Uncultured Microorganisms
    2000 780 citations Michelle R. Rondon, Paul R. August et al. Applied and Environmental Microbiology profile →
  2. A developmental switch in thymic lymphocyte maturation potential occurs at the level of hematopoietic stem cells
    1990 528 citations Koichi Ikuta, Tatsuo Kina et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ian A. MacNeil United States 13 1.1k 443 426 183 173 25 2.0k
Lingyun Li China 27 1.5k 1.4× 316 0.7× 83 0.2× 294 1.6× 76 0.4× 73 2.4k
Mepur H. Ravindranath United States 26 1.0k 0.9× 1.2k 2.7× 151 0.4× 372 2.0× 33 0.2× 116 2.3k
Juan F. Linares United States 23 2.1k 1.8× 301 0.7× 223 0.5× 395 2.2× 238 1.4× 30 3.3k
Karen McGovern United States 17 1.4k 1.3× 349 0.8× 120 0.3× 378 2.1× 101 0.6× 48 2.2k
Klaus G. Steube Germany 24 603 0.5× 248 0.6× 57 0.1× 243 1.3× 311 1.8× 53 1.5k
Adam Platt United Kingdom 25 1.3k 1.2× 261 0.6× 76 0.2× 270 1.5× 119 0.7× 53 2.4k
Petr Müller Czechia 28 1.4k 1.2× 199 0.4× 160 0.4× 533 2.9× 42 0.2× 106 2.5k
Jeyanthy Eswaran United Kingdom 27 1.5k 1.3× 136 0.3× 126 0.3× 509 2.8× 95 0.5× 41 2.4k
Brian C. W. Hummel Canada 10 1.1k 1.0× 278 0.6× 68 0.2× 199 1.1× 69 0.4× 24 2.2k
Luca Federici Italy 32 2.0k 1.8× 193 0.4× 70 0.2× 242 1.3× 62 0.4× 92 3.4k

Countries citing papers authored by Ian A. MacNeil

Since Specialization
Citations

This map shows the geographic impact of Ian A. MacNeil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian A. MacNeil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian A. MacNeil more than expected).

Fields of papers citing papers by Ian A. MacNeil

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian A. MacNeil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian A. MacNeil. The network helps show where Ian A. MacNeil may publish in the future.

Co-authorship network of co-authors of Ian A. MacNeil

This figure shows the co-authorship network connecting the top 25 collaborators of Ian A. MacNeil. A scholar is included among the top collaborators of Ian A. MacNeil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian A. MacNeil. Ian A. MacNeil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khan, Salmaan, Stefano Rossetti, Ian A. MacNeil, et al.. (2024). Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway. Molecular Oncology. 19(1). 225–247. 4 indexed citations
2.
Rossetti, Stefano, Salmaan Khan, Ian A. MacNeil, et al.. (2024). Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models. npj Breast Cancer. 10(1). 40–40. 14 indexed citations
3.
4.
5.
Sen, Adrish, Salmaan Khan, Ian A. MacNeil, et al.. (2023). Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.. Journal of Clinical Oncology. 41(6_suppl). 149–149. 2 indexed citations
6.
MacNeil, Ian A., et al.. (2022). Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy. Cell Communication and Signaling. 20(1). 4–4. 2 indexed citations
7.
MacNeil, Ian A., David J. Burns, Benjamin E. Rich, et al.. (2020). New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified. Journal of Cancer Research and Clinical Oncology. 146(3). 605–619. 5 indexed citations
8.
Laing, Lance, et al.. (2020). Test identifies ovarian cancer patients with hyperactive c-Met and ErbB signaling tumors who may benefit from c-Met and pan-HER combination therapy.. Journal of Clinical Oncology. 38(15_suppl). e18038–e18038. 1 indexed citations
9.
Burns, David J., Benjamin E. Rich, Ian A. MacNeil, et al.. (2017). Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells. BMC Cancer. 17(1). 199–199. 14 indexed citations
10.
Burns, David J., Benjamin E. Rich, Ian A. MacNeil, et al.. (2016). A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity. Oncotarget. 7(48). 78577–78590. 3 indexed citations
11.
Dalgarno, David C., Thilo Stehle, Surinder S. Narula, et al.. (2005). Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine‐based Compounds. Chemical Biology & Drug Design. 67(1). 46–57. 65 indexed citations
12.
13.
Rondon, Michelle R., Paul R. August, Alan D. Bettermann, et al.. (2000). Cloning the Soil Metagenome: a Strategy for Accessing the Genetic and Functional Diversity of Uncultured Microorganisms. Applied and Environmental Microbiology. 66(6). 2541–2547. 780 indexed citations breakdown →
14.
Lynch, Berkley A., Charles A. Minor, Kara A. Loiacono, et al.. (1999). Simultaneous Assay of Src SH3 and SH2 Domain Binding Using Different Wavelength Fluorescence Polarization Probes. Analytical Biochemistry. 275(1). 62–73. 16 indexed citations
15.
Buchanan, John L., Chi B. Vu, Michael G. Yang, et al.. (1999). Structure-activity relationships of a novel class of Src SH2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 9(16). 2359–2364. 32 indexed citations
16.
Lynch, Berkley A., et al.. (1997). A Fluorescence Polarization Based Src-SH2 Binding Assay. Analytical Biochemistry. 247(1). 77–82. 81 indexed citations
17.
Ikuta, Koichi, Tatsuo Kina, Ian A. MacNeil, et al.. (1992). Development of γδ T‐cell Subsets from Fetal Hematopoietic Stem Cellsa. Annals of the New York Academy of Sciences. 651(1). 21–32. 5 indexed citations
18.
Suda, Takashi, Ian A. MacNeil, Melissa A. Fischer, Kevin W. Moore, & Albert Zlotnik. (1991). Identification of a Novel Thymocyte Growth Factor Derived from B Cell Lymphomas. Advances in experimental medicine and biology. 292. 115–120. 2 indexed citations
19.
Suda, Takashi, Anne O’Garra, Ian A. MacNeil, et al.. (1990). Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas. Cellular Immunology. 129(1). 228–240. 80 indexed citations
20.
Ikuta, Koichi, Tatsuo Kina, Ian A. MacNeil, et al.. (1990). A developmental switch in thymic lymphocyte maturation potential occurs at the level of hematopoietic stem cells. Cell. 62(5). 863–874. 528 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lingyun Li Breakdown of academic impact, for papers by Mepur H. Ravindranath Breakdown of academic impact, for papers by Juan F. Linares Breakdown of academic impact, for papers by Karen McGovern Breakdown of academic impact, for papers by Klaus G. Steube Breakdown of academic impact, for papers by Adam Platt Breakdown of academic impact, for papers by Petr Müller Breakdown of academic impact, for papers by Jeyanthy Eswaran Breakdown of academic impact, for papers by Brian C. W. Hummel Breakdown of academic impact, for papers by Luca Federici
Rankless by CCL
2026